Thomas Gajewski to Immunomodulation
This is a "connection" page, showing publications Thomas Gajewski has written about Immunomodulation.
Connection Strength
0.446
-
Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-?-signaling mutant cancer cells. Nat Commun. 2020 01 30; 11(1):602.
Score: 0.156
-
STING pathway agonism as a cancer therapeutic. Immunol Rev. 2019 07; 290(1):24-38.
Score: 0.150
-
Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunol Res. 2016 07; 4(7):563-8.
Score: 0.121
-
Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 2010 Jul; 51(7):1241-50.
Score: 0.020